

## Proposed Fujifilm Development and Commercialisation Transaction

**Melbourne, Australia; 29 December 2016:** Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), continues to work closely with Fujifilm to finalise definitive agreements in respect of a proposed transaction for the development and commercialisation of certain Cynata technology, including Cynata's lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001.

Cynata Managing Director and Chief Executive Officer Dr Ross Macdonald said, "In the past several months the parties have made great progress toward finalising the various contracts that govern the proposed strategic relationship and look forward to the successful conclusion of our ongoing discussions. We expect to complete the transaction soon".

**CONTACTS:** Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email [stewart.washer@cynata.com](mailto:stewart.washer@cynata.com)  
Rudi Michelson, Monsoon, Australia Media Contact, 0411 402 737, [rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

### About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

### About Fujifilm Corporation

FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings. The company brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic and thin film coating technologies. The Fujifilm Group is a leader in the field of regenerative medicine. US Cellular Dynamics International, Inc., has also joined the Fujifilm Group in 2015, and Fujifilm is leveraging iPSC production technologies to create an iPSC bank that comprises iPSCs for use in researching various diseases and conditions. The decision to bring these highly innovative companies into the Group further emphasizes Fujifilm's dedication to achieving leadership in the field of regenerative medicine and to meet unmet medical needs.

For more information, please visit: [www.fujifilmholdings.com](http://www.fujifilmholdings.com).